| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b74452a889073845b47a40e23c273814 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D279-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-583
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D279-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-54 |
| filingDate |
2008-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5674d0242b5fadc3dc4e3aedb8daa6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08039f8d258f7f193d7c45129f3492f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d5e1ba9cd30a64b465e9dc6bb7097c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f90915c5c3705534bcf159cefdda5e3 |
| publicationDate |
2010-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7713962-B2 |
| titleOfInvention |
Neurofibrillary labels |
| abstract |
A method for determining the Braak stage of neurofibrillary degeneration associated with a tauopathy in a subject having neurofibrillary degeneration is disclosed. The method comprises the steps of (i) administering to the subject a conjugated, chelated or detectable chemical group-associated ligand that labels aggregated paired helical filament (PHF) tau protein and is capable of crossing the blood brain barrier; (ii) determining the presence and\or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, and (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. Preferred ligands include sulphonated-benzothiazole-like compounds and diamonophenothiazines. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9588129-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9464064-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013036749-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10894822-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8703137-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11155609-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11673944-B2 |
| priorityDate |
2001-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |